文献速递胸部肿瘤

特泊替尼联合奥希替尼治疗一线奥希替尼进展后MET扩增的EGFR突变非小细胞肺癌患者(INSIGHT 2):一项多中心、开放标签、2期试验

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2024-01-01

这项多中心、开放标签、2期INSIGHT 2研究在17个国家179个中心纳入128例一线奥希替尼进展后MET扩增的EGFR突变非小细胞肺癌患者,接受特泊替尼500 mg联合奥希替尼80 mg每日一次口服。中心FISH确认MET扩增且随访至少9个月的98例患者中,确认客观缓解率为50.0%(95% CI 39.7-60.3)。研究者认为该联合方案显示出有前景的活性和可接受的安全性,提示一种潜在免化疗的口服靶向治疗选择,应进一步研究。

要点

  • 中心FISH确认MET扩增且随访至少9个月的患者确认客观缓解率为50.0%(95% CI 39.7-60.3)。
  • 最常见的治疗相关≥3级不良事件为外周水肿6例(5%)、食欲下降5例(4%)、心电图QT间期延长5例(4%)、肺炎4例(3%)。
  • 16例(13%)患者报告治疗相关严重不良事件;4例(3%)死亡被研究者评估为可能与试验药物相关。

核心结论

  • 特泊替尼联合奥希替尼在EGFR突变非小细胞肺癌且MET扩增作为一线奥希替尼耐药机制的患者中显示出有前景的活性和可接受的安全性,提示一种潜在免化疗的口服靶向治疗选择,应进一步研究。

研究设计与样本

  • 多中心、开放标签、2期研究,在17个国家的179个学术中心和社区诊所开展。
  • 纳入年龄≥18岁、ECOG体能状态0或1、任何组织学类型的晚期或转移性EGFR突变非小细胞肺癌患者,组织活检FISH显示MET扩增(MET基因拷贝数≥5或MET/CEP7比值≥2)或液体活检NGS显示MET血浆基因拷贝数≥2.3,且一线奥希替尼进展。
  • 患者接受口服特泊替尼500 mg联合口服奥希替尼80 mg每日一次。
  • 主要终点为经中心FISH确认MET扩增、接受特泊替尼联合奥希替尼且随访至少9个月患者的独立评估客观缓解。
  • 安全性在至少接受一剂研究药物的患者中分析;研究注册号ClinicalTrials.gov NCT03940703(入组已完成)。

主要发现

  • 2020年2月13日至2022年11月4日,128例患者(女性74例[58%],男性54例[42%])入组并开始特泊替尼联合奥希替尼治疗。
  • 主要活性分析人群包括98例经中心FISH确认MET扩增、既往一线奥希替尼治疗且随访至少9个月的患者(中位随访12.7个月[IQR 9.9-20.3])。
  • 确认客观缓解率为50.0%(95% CI 39.7-60.3;98例中49例)。
  • 最常见的治疗相关≥3级不良事件为外周水肿6例(5%)、食欲下降5例(4%)、心电图QT间期延长5例(4%)、肺炎4例(3%)。
  • 16例(13%)患者报告治疗相关严重不良事件;4例(3%)患者死亡被研究者评估为可能与任一试验药物相关,原因包括肺炎2例(2%)、血小板计数下降1例(1%)、呼吸衰竭1例(1%)、呼吸困难1例(1%);其中1例死亡归因于肺炎和呼吸困难两者。

临床怎么用

  • 作者认为,特泊替尼联合奥希替尼在EGFR突变非小细胞肺癌且MET扩增作为一线奥希替尼耐药机制的患者中显示出有前景的活性和可接受的安全性,提示一种潜在免化疗的口服靶向治疗选择,应进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and MET amplification as a mechanism of resistance to first-line osimertinib have few treatment options. Here, we report the primary analysis of the phase 2 INSIGHT 2 study evaluating tepotinib, a highly selective MET inhibitor, combined with osimertinib in this population. METHODS: This open-label, phase 2 study was conducted at 179 academic centres and community clinics in 17 countries. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0 or 1 and advanced or metastatic EGFR-mutated NSCLC of any histology, with MET amplification by tissue biopsy fluorescence in-situ hybridisation (FISH; MET gene copy number of ≥5 or MET-to-CEP7 ratio of ≥2) or liquid biopsy next-generation sequencing (MET plasma gene copy number of ≥2·3), following progression on first-line osimertinib. Patients received oral tepotinib 500 mg plus oral osimertinib 80 mg once daily. The primary endpoint was independently assessed objective response in patients with MET amplification by central FISH treated with tepotinib plus osimertinib with at least 9 months of follow-up. Safety was analysed in patients who received at least one study drug dose. This study is registered with ClinicalTrials.gov, NCT03940703 (enrolment complete). FINDINGS: Between Feb 13, 2020, and Nov 4, 2022, 128 patients (74 [58%] female, 54 [42%] male) were enrolled and initiated tepotinib plus osimertinib. The primary activity analysis population included 98 patients with MET amplification confirmed by central FISH, previous first-line osimertinib and at least 9 months of follow-up (median 12·7 months [IQR 9·9-20·3]). The confirmed objective response rate was 50·0% (95% CI 39·7-60·3; 49 of 98 patients). The most common treatment-related grade 3 or worse adverse events were peripheral oedema (six [5%] of 128 patients), decreased appetite (five [4%]), prolonged electrocardiogram QT interval (five [4%]), and pneumonitis (four [3%]). Serious treatment-related adverse events were reported in 16 (13%) patients. Deaths of four (3%) patients were assessed as potentially related to either trial drug by the investigator due to pneumonitis (two [2%] patients), decreased platelet count (one [1%]), respiratory failure (one [1%]), and dyspnoea (one [1%]); one death was attributed to both pneumonitis and dyspnoea. INTERPRETATION: Tepotinib plus osimertinib showed promising activity and acceptable safety in patients with EGFR-mutated NSCLC and MET amplification as a mechanism of resistance to first-line osimertinib, suggesting a potential chemotherapy-sparing oral targeted therapy option that should be further investigated. FUNDING: Merck (CrossRef Funder ID: 10.13039/100009945).

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Wu YL, Guarneri V, Voon PJ, et al. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2024. PMID: 39089305. doi:10.1016/S1470-2045(24)00270-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。